JP2014530840A5 - - Google Patents

Download PDF

Info

Publication number
JP2014530840A5
JP2014530840A5 JP2014536265A JP2014536265A JP2014530840A5 JP 2014530840 A5 JP2014530840 A5 JP 2014530840A5 JP 2014536265 A JP2014536265 A JP 2014536265A JP 2014536265 A JP2014536265 A JP 2014536265A JP 2014530840 A5 JP2014530840 A5 JP 2014530840A5
Authority
JP
Japan
Prior art keywords
ohepa
hetre
dgla
acne
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014536265A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530840A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014530840A publication Critical patent/JP2014530840A/ja
Publication of JP2014530840A5 publication Critical patent/JP2014530840A5/ja
Pending legal-status Critical Current

Links

JP2014536265A 2011-10-19 2012-10-19 Ｄｇｌａ、１５−ｏｈｅｐａおよび／または１５−ｈｅｔｒｅを含む医薬組成物、ならびにその使用方法 Pending JP2014530840A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161549018P 2011-10-19 2011-10-19
US61/549,018 2011-10-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017132132A Division JP2017226664A (ja) 2011-10-19 2017-07-05 Ｄｇｌａ、１５−ｏｈｅｐａおよび／または１５−ｈｅｔｒｅを含む医薬組成物、ならびにその使用方法

Publications (2)

Publication Number Publication Date
JP2014530840A JP2014530840A (ja) 2014-11-20
JP2014530840A5 true JP2014530840A5 (enExample) 2015-12-10

Family

ID=46796104

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014536265A Pending JP2014530840A (ja) 2011-10-19 2012-10-19 Ｄｇｌａ、１５−ｏｈｅｐａおよび／または１５−ｈｅｔｒｅを含む医薬組成物、ならびにその使用方法
JP2017132132A Pending JP2017226664A (ja) 2011-10-19 2017-07-05 Ｄｇｌａ、１５−ｏｈｅｐａおよび／または１５−ｈｅｔｒｅを含む医薬組成物、ならびにその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017132132A Pending JP2017226664A (ja) 2011-10-19 2017-07-05 Ｄｇｌａ、１５−ｏｈｅｐａおよび／または１５−ｈｅｔｒｅを含む医薬組成物、ならびにその使用方法

Country Status (5)

Country Link
US (2) US8293790B2 (enExample)
EP (1) EP2768495A1 (enExample)
JP (2) JP2014530840A (enExample)
HK (1) HK1202415A1 (enExample)
WO (1) WO2013057284A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) * 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US20120264705A1 (en) * 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) * 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
US10017453B2 (en) 2013-11-15 2018-07-10 Ds Biopharma Limited Pharmaceutically acceptable salts of fatty acids
AU2015204531B2 (en) * 2014-01-10 2019-11-14 Afimmune Limited Pharmaceutical compositions comprising 15-HEPE and methods of treating asthma and lung disorders using same
MA39718A (fr) * 2014-04-09 2017-02-15 Dignity Sciences Ltd Compositions et méthodes d'utilisation de celles-ci
MX375738B (es) * 2014-05-12 2025-03-06 Unilever Ip Holdings B V Niacinamida para inducir generacion de peptidos antimicrobianos.
JP2017516823A (ja) 2014-06-04 2017-06-22 ディグニティ サイエンシス リミテッド Ｄｇｌａを含む薬学的組成物及びその使用
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
MA47141A (fr) * 2015-05-13 2019-11-06 Ds Biopharma Ltd Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation
US20170020836A1 (en) 2015-07-21 2017-01-26 Dignity Sciences Limited Compositions Comprising 15-HEPE and Methods of Treating or Preventing Cancer and Neurologic Disease
RU2737089C2 (ru) 2015-12-18 2020-11-24 Эфиммьюн Лимитед Композиции, содержащие 15-hepe, и способы их применения
CN111050738A (zh) 2017-08-30 2020-04-21 荷兰联合利华有限公司 个人护理组合物
US11504327B1 (en) 2019-01-21 2022-11-22 Eric Morrison Method of preparing nanoparticles by hot-melt extrusion
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
FR3148365A1 (fr) * 2023-05-04 2024-11-08 Pierre Fabre Dermo-Cosmetique Oxylipines dans le traitement de la séborrhée et/ou de l’acné

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5264452A (en) 1975-11-18 1977-05-27 Nippon Suisan Kaisha Ltd Method of producing processed fish meat
JPS5820575B2 (ja) 1975-11-27 1983-04-23 日本水産株式会社 スイサンカコウヒンノセイゾウホウ
US4273763A (en) 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
US4444755A (en) 1978-01-23 1984-04-24 Efamol Limited Treatment for skin disorders
EP0004770B1 (en) 1978-04-11 1984-06-13 Efamol Limited Pharmaceutical and dietary composition comprising gamma-linolenic acids
IE49783B1 (en) 1979-05-18 1985-12-11 Efamol Ltd Pharmaceutical and dietary composition comprising epsilon-linolenic acids
IE51145B1 (en) 1980-03-07 1986-10-15 Efamol Ltd Pharmaceutical and dietary compositions
IE53332B1 (en) 1980-03-14 1988-10-26 Efamol Ltd Pharmaceutical compositions
US4386072A (en) 1981-06-26 1983-05-31 Horrobin David F Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor
US5324748A (en) 1981-07-14 1994-06-28 Efamol Limited Method for enhancement of 1-series PG production
US5145686A (en) 1982-02-03 1992-09-08 Efamol Limited Topical pharmaceutical compositions
ATE22532T1 (de) 1982-03-01 1986-10-15 Efamol Ltd Pharmazeutische zusammensetzung.
ATE19855T1 (de) 1982-03-01 1986-06-15 Efamol Ltd Pharmazeutische und diaetetische zusammensetzung.
EP0087864B1 (en) 1982-03-01 1986-10-15 Efamol Limited Pharmaceutical composition
EP0093516B1 (en) 1982-04-29 1986-10-01 Efamol Limited Pharmaceutical composition
GB8302708D0 (en) 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
GB8319073D0 (en) 1983-07-14 1983-08-17 Efamol Ltd Fatty acid compositions
GB8326130D0 (en) 1983-09-29 1983-11-02 Efamol Ltd Topical preparations containing tars and fatty acids
GB8420771D0 (en) 1984-08-15 1984-09-19 Efamol Ltd Treatment of skin disorders
GB8425006D0 (en) 1984-10-03 1984-11-07 Efamol Ltd Composition of copper/fatty acids
GB8506027D0 (en) 1985-03-08 1985-04-11 Efamol Ltd Pharmaceutical & dietary compositions
GB8522670D0 (en) 1985-09-13 1985-10-16 Efamol Ltd Drug treatments
GB8524275D0 (en) 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
US5198468A (en) 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
EP0309086A1 (en) 1987-09-07 1989-03-29 Efamol Holdings Plc Treatment of male pattern baldness and of unwanted hair growth
GB8729153D0 (en) 1987-12-14 1988-01-27 Efamol Ltd Fatty acid compositions
EP0561766B1 (en) 1988-01-14 1995-11-02 FRITHZ, Anders Use of essential fatty acids for the preparation of a drug for the treatment of eczema
GB8806737D0 (en) 1988-03-22 1988-04-20 Efamol Holdings Therapeutic composition & method
GB8916734D0 (en) 1989-07-21 1989-09-06 Efamol Holdings Pharmaceutical and dietary uses of fatty acids
GB8918294D0 (en) 1989-08-10 1989-09-20 Efamol Holdings Pharmaceutical compositions
GB8920228D0 (en) 1989-09-07 1989-10-18 Efamol Holdings Fatty acid therapy
JPH04290820A (ja) 1991-03-18 1992-10-15 Idemitsu Petrochem Co Ltd 皮膚病犬の治療方法とその薬剤
KR930006432B1 (ko) 1991-04-10 1993-07-16 주식회사 우방랜드 아이코사펜타노산 및 α-리놀렌산을 함유하는 여드름 치료제 조성물
GB9111900D0 (en) 1991-06-03 1991-07-24 Efamol Holdings Fatty acid compositions
GB9112052D0 (en) 1991-06-05 1991-07-24 Efamol Holdings Fatty acid treatment
GB9211229D0 (en) 1992-05-27 1992-07-08 Efamol Holdings Fatty acid treatment
US5605929A (en) * 1992-05-27 1997-02-25 Arch Development Corp. Methods and compositions for inhibiting 5α-reductase activity
GB9217780D0 (en) 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
US5888541A (en) 1992-08-21 1999-03-30 Scotia Holdings Plc Fatty acid treatment
GB9301446D0 (en) 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
CA2119000A1 (en) 1993-03-19 1994-09-20 David Frederick Horrobin Formulation for use in smokers
US5409955A (en) 1993-05-13 1995-04-25 Bockow; Barry I. Compositions and methods for inhibiting uterine contractility
GB9403855D0 (en) 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
AU711482B2 (en) 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
US5709855A (en) 1995-09-22 1998-01-20 Bockow; Barry I. Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain
GB9621373D0 (en) 1996-10-14 1996-12-04 Scotia Holdings Plc Fatty acid treatment
GB9710351D0 (en) 1997-05-20 1997-07-16 Scotia Holdings Plc Glucosamine fatty acids
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
AU6503699A (en) 1998-10-05 2000-04-26 Abbott Laboratories Altered fatty acid biosynthesis in insect cells using delta five desaturase
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
CA2304906A1 (en) 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
GB0016452D0 (en) 2000-07-04 2000-08-23 Kilgowan Limited Vitamin K and essential fatty acids
DE10121252A1 (de) * 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
US6462084B1 (en) 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
CN1268328C (zh) 2001-05-30 2006-08-09 拉克斯戴尔有限公司 辅酶q与二十碳五烯酸(epa)
US20030073930A1 (en) 2001-10-17 2003-04-17 Morrissey Gerald R. Methods and device for preventing or healing injured nipples or areolas in mammalian females or for obtaining samples from nipples in mammalian females
US20030105445A1 (en) 2001-11-30 2003-06-05 Kimberly-Clark Worldwide, Inc. Breast pad assembly containing a skin benefit ingredient
US20030194446A1 (en) 2002-04-10 2003-10-16 Akes Lindy K. Zinc oxide compositions for dermatheraputics
AU2003299034A1 (en) 2002-09-20 2004-04-08 Griscom Bettle Iii Transdermal compositions
DE102004031210A1 (de) 2004-06-28 2006-02-09 Trommsdorff Gmbh & Co. Kg MLV-Kosmetikum
CA2533421A1 (en) * 2003-07-23 2005-02-03 Xoma Technology Ltd. Use of xmp-629 for the treatment of acne
US20070105954A1 (en) 2003-12-31 2007-05-10 Ingennus Limited Formulation containing a carboxylic acid or an ester thereof
US7807849B2 (en) 2004-04-22 2010-10-05 Commonwealth Scientific And Industrial Research Organisation Synthesis of long-chain polyunsaturated fatty acids by recombinant cells
CN101043884A (zh) 2004-07-01 2007-09-26 谢彭斯眼科研究公司 用于治疗眼部疾病和病症的组合物和方法
JP2006306812A (ja) 2005-04-28 2006-11-09 Suntory Ltd 好酸球浸潤抑制剤
JP5546087B2 (ja) 2005-02-14 2014-07-09 サントリーホールディングス株式会社 皮膚疾患経口治療または予防剤
EP1852114B1 (en) 2005-02-14 2019-09-18 Suntory Holdings Limited Composition containing dihomo-y-linolenic acid (dgla) as active ingredient
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
CA2674210A1 (en) 2005-12-30 2007-07-12 Intradigm Corporation Sirna compositions promoting scar-free wound healing of skin and methods for wound treatment
CA2649337C (en) 2006-04-13 2014-11-18 Nippon Suisan Kaisha, Ltd. Process for preparing concentrated polyunsaturated fatty acid oil
GB0611240D0 (en) 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
FR2906716B1 (fr) 2006-10-06 2013-05-17 Clarins Lab Utilisation d'une composition cosmetique pour le soin des peaux grasses.
US20080125487A1 (en) 2006-11-17 2008-05-29 Tapas Das Elongase gene and uses thereof
WO2008070129A2 (en) 2006-12-05 2008-06-12 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
US20100144009A1 (en) 2006-12-20 2010-06-10 Protech Research Pty Ltd. Extracting And Purifying Lipoxygenase
US20080213357A1 (en) 2007-02-12 2008-09-04 Andrew Bruce Hebard Plant Derived Lipid Useful for Nutraceutical and Cosemeceutical Applications
ITMI20070555A1 (it) 2007-03-21 2007-06-20 Giuliani Spa Composizione provvista di attivita' di inibizione sulla 5 alfa-reduttasi
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
JP2011519552A (ja) 2008-04-25 2011-07-14 ビーエーエスエフ プラント サイエンス ゲーエムベーハー 植物種子油
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
GB0907601D0 (en) 2009-05-01 2009-06-10 Equateq Ltd Novel methods
US8524485B2 (en) 2009-06-16 2013-09-03 E I Du Pont De Nemours And Company Long chain omega-3 and omega-6 polyunsaturated fatty acid biosynthesis by expression of acyl-CoA lysophospholipid acyltransferases
US8188335B2 (en) 2009-07-17 2012-05-29 Abbott Laboratories Δ9-elongase for production of polyunsaturated fatty acid-enriched oils
US20110082216A1 (en) 2009-10-02 2011-04-07 Wu Jeffrey M Benzoyl peroxide composition for treating skin
AU2011349718B2 (en) 2010-12-21 2017-02-09 Nestec S.A. Methods and compositions for preventing and treating osteoarthritis
EP2508180A1 (en) 2011-04-04 2012-10-10 Nestec S.A. Sn-1(3) Monoacylglycerides and lipid absorption
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
EP2768496A1 (en) 2011-10-19 2014-08-27 Dignity Sciences Limited Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
AU2012345942A1 (en) 2011-11-29 2014-06-12 Dignity Sciences Limited Compositions comprising 20-carbon fatty acids and methods of making and using same
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
WO2014022816A2 (en) 2012-08-03 2014-02-06 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hetre and methods of treating or preventing arthritis using same
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same

Similar Documents

Publication Publication Date Title
JP2014530840A5 (enExample)
JP2015512729A5 (enExample)
JP2016515522A5 (enExample)
JP2013525942A5 (enExample)
JP2015503422A5 (enExample)
JP2013540852A5 (enExample)
JP2012143233A5 (enExample)
JP2011170856A5 (enExample)
JP2015528502A5 (enExample)
JP2016530351A5 (enExample)
JP2015504870A5 (enExample)
SI2755473T1 (sl) Paraziticidni sestavki, ki obsegajo izoksazolinsko učinkovino, postopki in uporabe le-teh
SI2739615T1 (sl) Fenil-3-aza-biciklo(3.1.0)heks-3-il-metanoni in njihova uporaba kot zdravilo
IL230635A0 (en) A novel 1,2,3,4-tetrahydroquinoline derivative useful for the treatment of diabetes
ZA201401678B (en) Novel distributed 3,4-diamino-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
JP2013181136A5 (ja) ポリイミド前駆体組成物、ポリイミド成形体、及び画像形成装置
PL2726470T3 (pl) Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych
JP2013538128A5 (enExample)
JP2013536184A5 (enExample)
JP2013231052A5 (enExample)
JP2012044147A5 (enExample)
JP2011170857A5 (enExample)
JP2011181497A5 (enExample)
HK1203379A1 (en) β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
JP2017516883A5 (enExample)